NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03099382,Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer,https://clinicaltrials.gov/study/NCT03099382,,COMPLETED,"In this study, participants with advanced or metastatic squamous cell carcinoma of the esophagus that has progressed after first-line standard therapy will be randomized to receive either single agent SHR-1210 or the Investigator's choice of standard therapy with docetaxel or irinotecan. The primary study hypothesis is that treatment with SHR-1210 will prolong overall survival (OS) as compared to treatment with standard therapy.",YES,Esophageal Carcinoma,BIOLOGICAL: camrelizumab|DRUG: Docetaxel|DRUG: Irinotecan,"Overall Survival (OS), approximately 24 months",,,"Jiangsu HengRui Medicine Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,457,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,SHR-1210-III-301-ESC,2017-05-05,2019-05-06,2019-05-06,2017-04-04,2024-01-22,2024-01-22,"307 Hospital of PLA, Beijing, Beijing, China|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/82/NCT03099382/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/82/NCT03099382/SAP_001.pdf"
